154 research outputs found
Dual-curing, self-adhesive resin cement: influence of the polymerization modes on the degree of conversion and microhardness
Effect of environments on the estimated genetic potential of segregating common bean populations
Incidência de úlceras por pressão em pacientes de Unidade de Terapia Intensiva Cardiopneumológica
The nursing process presented as routine care actions: building its meaning in clinical nurses' perspective
O Programa Mais Médicos: provimento de médicos em municÃpios brasileiros prioritários entre 2013 e 2014
Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis
All rights reserved. Visceral leishmaniasis (VL) is one of the most important tropical diseases worldwide. Although chemotherapy has been widely used to treat this disease, problems related to the development of parasite resistance and side effects associated with the compounds used have been noted. Hence, alternative approaches for VL control are desirable. Some methods, such as vector control and culling of infected dogs, are insufficiently effective, with the latter not ethically recommended. The development of vaccines to prevent VL is a feasible and desirable measure for disease control, for example, some vaccines designed to protect dogs against VL have recently been brought to market. These vaccines are based on the combination of parasite fractions or recombinant proteins with adjuvants that are able to induce cellular immune responses, however, their partial efficacy and the absence of a vaccine to protect against human leishmaniasis underline the need for characterization of new vaccine candidates. This review presents recent advances in control measures for VL based on vaccine development, describing extensively studied antigens, as well as new antigenic proteins recently identified using immuno-proteomic techniquesThis work was supported by grants from Instituto Nacional de Ciência e Tecnologia em Nano-Biofarmacêutica, Rede Nanobiotec/Brasil-Universidade Federal de Uberlândia/CAPES, PRONEX-FAPEMIG (APQ-01019-09), FAPEMIG (CBB-APQ-00819-12 and CBB-APQ-01778-2014), and CNPq (APQ-482976/2012-8, APQ-488237/2013-0, and APQ-467640/2014-9). EAFC and LRG are recipients of the grant from CNPq. MACF is the recipient of grants from FAPEMIG/CAPE
Primary dengue haemorrhagic fever in patients from northeast of Brazil is associated with high levels of interferon-β during acute phase
Sulfonated polyaniline: influence of sulfonation routes on its thermal and structural characteristics
Processing and Characterization of PET Composites Reinforced With Geopolymer Concrete Waste
- …